Ji Yanli, Luo Guangping, Fu Yongshui
Institute of Clinical Blood Transfusion, Guangzhou Blood Center, Guangzhou, People's Republic of China.
Vox Sang. 2022 May;117(5):633-640. doi: 10.1111/vox.13232. Epub 2022 Jan 10.
The transfusion of D-negative red blood cells (RBCs) to D-negative patients has been widely adopted to prevent anti-D alloimmunization, especially in women of childbearing age. Still, transfusion of D-positive RBCs to D-negative recipients is occasionally inevitable in practice, and the resulting incidence of anti-D in different D-negative groups of patients has not been well summarized.
We searched the relevant literature using PubMed, Cochrane Library, and Embase databases from inception date to 30 September 2021. We looked for studies of anti-D occurring in D-negative recipients who received D-positive RBC transfusions. The anti-D incidence was summarized with 95% confidence intervals (CIs). Data with similar characteristics were combined using a random-effects model.
About 42 studies (2226 cases), which found anti-D, the exact volume of D-positive RBC transfused, and the follow-up time for anti-D detection, met the inclusion criteria. The pooled anti-D incidence was 64% (95% CI, range 55%-74%) in volunteers receiving small volumes of D-positive RBCs, 84% (95% CI, 74%-94%) in those receiving whole units, 26% (95% CI, 19%-32%) in mixed patients, 12% (95% CI, 8%-16%) in oncology patients, 27% (95% CI, 13%-40%) in trauma patients, 4% (95% CI, 0%-8%) in immune-compromised transplant patients, and 6% (95% CI, 1%-39%) in those with AIDS.
Compared with the high frequency of anti-D in healthy D-negative volunteers given D-positive RBCs, we found a lower rate of anti-D immunization in various D-negative patients and almost none in transplant and AIDS patients.
向D阴性患者输注D阴性红细胞(RBCs)已被广泛采用以预防抗D同种免疫,尤其是在育龄妇女中。然而,在实际操作中,向D阴性受血者输注D阳性RBCs有时仍不可避免,且不同D阴性患者群体中由此产生的抗D发生率尚未得到很好的总结。
我们使用PubMed、Cochrane图书馆和Embase数据库,检索了从起始日期至2021年9月30日的相关文献。我们查找了接受D阳性RBC输血的D阴性受血者中抗D发生情况的研究。抗D发生率用95%置信区间(CIs)进行总结。具有相似特征的数据使用随机效应模型进行合并。
约42项研究(2226例)符合纳入标准,这些研究发现了抗D、输注的D阳性RBC的确切体积以及抗D检测的随访时间。接受少量D阳性RBCs的志愿者中抗D合并发生率为64%(95%CI,范围55%-74%),接受全单位血液的患者中为84%(95%CI,74%-94%),混合患者中为26%(95%CI,19%-32%),肿瘤患者中为12%(95%CI,8%-16%),创伤患者中为27%(95%CI,13%-40%),免疫功能低下的移植患者中为4%(95%CI,0%-8%),艾滋病患者中为6%(95%CI,1%-39%)。
与接受D阳性RBCs的健康D阴性志愿者中抗D的高发生率相比,我们发现在各种D阴性患者中抗D免疫发生率较低,而在移植患者和艾滋病患者中几乎没有。